H5N1 News and Research

Latest H5N1 News and Research

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax's single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta.

15 Nov 2012

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.

23 Oct 2012

Significant increase in genomic Replikin Count of human SARS virus

The identification of the virus responsible for a second case of SARS-like respiratory virus, "London1_novel CoV 2012", has raised concerns over the risk of the disease spreading. These concerns may be justified given the observed rise in virus's genomic Replikin Count.

6 Oct 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Climate change associated with increased risk of avian flu transmission in wild birds

Rising sea levels, melting glaciers, more intense rainstorms and more frequent heat waves are among the planetary woes that may come to mind when climate change is mentioned. Now, two University of Michigan researchers say an increased risk of avian influenza transmission in wild birds can be added to the list.

30 Aug 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

16 Aug 2012

Orally effective FluCide anti-influenza drug candidate

NanoViricides, Inc. announced today that an anti-influenza drug candidate under its FluCide program is effective when given orally. The Company has received information that a FluCide drug candidate designed for oral administration has shown very strong efficacy in corresponding animal studies.

13 Aug 2012

Inovio commences SynCon vaccine phase I study in H1N1 influenza

Inovio Pharmaceuticals, Inc. announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon universal influenza vaccine.

10 Jul 2012

Research highlights three factors that could determine outbreak of pandemic flu

A major collaboration between US research centers has highlighted three factors that could ultimately determine whether an outbreak of influenza becomes a serious epidemic that threatens national health. The research suggests that the numbers in current response plans could be out by a factor of two or more depending on the characteristics of the particular pandemic influenza.

3 Jul 2012

More sophisticated process needed to vet research for possible security threats

Noting that the journal Science last week published the second of two controversial bird flu research papers, in which a team led by Ron Fouchier of the Erasmus Medical Center in Rotterdam created a mutated strain of the virus that spreads easily among ferrets, a Washington Post editorial writes that "this is not the end of the story. Rather, it marks the beginning of an important chapter for both science and security."

29 Jun 2012

Congressman 'dissatisfied' with handling of controversial H5N1 papers calls for cohesive policy for handling 'risky' research

"Dissatisfied with the government's handling of two research papers on mutant forms of avian influenza," Rep. Jim Sensenbrenner (R-Wisc.) on Wednesday "said that the lack of a cohesive policy for handling risky research funded by the National Institutes of Health (NIH) and other federal agencies could necessitate new laws, a situation that researchers have been trying to avoid," the Nature News Blog reports.

29 Jun 2012

New York Times examines bird flu studies, history of controversy

The New York Times examines several studies published in the journals Nature and Science looking at how the H5N1 bird flu virus could mutate to become more virulent among humans and outlines the history of controversy surrounding the studies.

27 Jun 2012

Sinovac provides update on EV71 vaccine Phase III trial on HFMD

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD).

26 Jun 2012

Censoring 'dual-use' scientific research not an effective strategy to mitigate security risks

"It's easy to get the impression that recent controversy over research into mutated versions of the H5N1 flu virus has created a clear split between a scientific community that wants the research to proceed and the results to be published and a biosecurity community that doesn't," biological-weapons expert Tim Trevan writes in this Nature opinion piece.

23 Jun 2012

U.S. journal Science publishes controversial H5N1 research

The U.S. journal Science on Thursday published the results of a controversial study in which researchers at the Erasmus Medical Center in the Netherlands "identified five mutations apparently necessary to make the [H5N1] bird flu virus spread easily among ferrets, which catch the same flus that humans do," the New York Times reports (McNeil, 6/21).

22 Jun 2012

VaxInnate commences VAX161 Phase I trial in pandemic avian influenza

VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.

13 Jun 2012

WHO hopes to host second meeting on issues related to 'dual-use' research

"The World Health Organization (WHO) hopes to hold a meeting late this fall to discuss 'dual-use' research issues raised in the controversy over publication of two studies involving lab-modified H5N1 viruses with increased transmissibility, a WHO official said," CIDRAP News reports.

1 Jun 2012

Single test developed that detects all known strains of H5N1

The close collaboration between scientists from the Experimental Therapeutics Centre (ETC) under the Agency for Science and Technology Research (A*STAR) and clinicians from Tan Tock Seng Hospital (TTSH) has enabled the successful development of the most comprehensive and rapid H5N1 bird flu test kit available to date.

29 May 2012